spacer
home > ebr > autumn 2017 > signal detection
PUBLICATIONS
European Biopharmaceutical Review

Signal Detection

Breast cancer is the most common cancer in women worldwide, with nearly 1.7 million new cases diagnosed in 2012 and a five year prevalence of 6.23 million. About 400,000 cases per year take place in Europe, 315,000 in the US and 460,000 in the rest of the world (1). This represents about 12% of all new cancer cases and 25% of all cancers in women.

There are three major types of breast cancer, characterised by the presence of key biomarkers: oestrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor (HER2). A fourth type, characterised by the lack of all three biomarkers, is informally known as triple-negative.

However, there is another type of breast cancer, which is very aggressive, extremely difficult to diagnose at presentation and ‘hidden’ among ER, PR, HER2 and triple-negative expressing tumours. It used to be referred to as the ‘aggressive type’ and has only recently been named basal-like breast cancer (BLBC) (2-4) (see Figure 1).

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Partha S Ray obtained his MD degree from Drexel University College of Medicine, US. He went on to complete surgical residency training in the US, followed by a surgical oncology fellowship at the John Wayne Cancer Institute, US. He is currently Professor and Head of Surgical Oncology at HCG Oncology, India.

Dr Roberto Fagnani has a PhD in pharmacology from the University of Milano, Italy. He has academic experience at The National Cancer Institute, US, and the University of California, US. Roberto gained industry experience at Hybritech and Eli Lilly & Co, has had multiple advisory roles at various biotechnology companies and Venture Capital firms and has co-founded three ventures.

spacer
Dr Partha S Ray
spacer
spacer
spacer
Dr Roberto Fagnani
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Lynparza recommended for approval in EU by CHMP for BRCA-mutated metastatic pancreatic cancer

AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) today announced that Lynparza (olaparib) has been recommended for marketing authorisation in the European Union (EU) for the 1st-line maintenance treatment of patients with germline BRCA-mutated (gBRCAm) metastatic pancreatic cancer. The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the Phase III POLO trial, which were published in The New England Journal of Medicine.
More info >>

White Papers

Streamlining patient recruitment using EHR data

The field of (bio)pharmaceutical research is booming. Increasingly more innovative therapeutics are being developed with the ability to drastically improve the quality of life of millions of patients around the world. Rigorously testing each of these candidate drugs for their safety and efficacy is an essential part of the development process. As the number of clinical trials steadily increases, the search for patients who present a specific medical profile and are willing to participate intensifies.
More info >>

 
Industry Events

Formulation and Drug Delivery Series UK

8-9 July 2020, Oxford Global

This event brings together leading formulation, drug delivery and biologics manufacturing experts from around the world across two days. The panel of prominent industry leaders and world-leading scientists will share the latest case studies, innovative developments for novel therapeutic products and strategies for drug development.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement